Bruce E Strober1,2, Rebecca Germino3, Adriana Guana3, Jeffrey D Greenberg4,5, Heather J Litman4, Ning Guo4, Mark Lebwohl6. 1. Department of Dermatology, University of Connecticut Health Center, Farmington, CT, USA. 2. Probity Medical Research, Waterloo, Canada. 3. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. 4. Corrona, LLC, Waltham, MA, USA. 5. New York University School of Medicine, New York, NY, USA. 6. Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Abstract
Objective: To examine the real-world effectiveness of secukinumab with regard to clinical and patient-reported outcomes (PROs) from enrollment to a 6-month follow-up visit in patients with psoriasis in the Corrona Psoriasis Registry. Methods: Eligible patients aged ≥ 18 years who initiated secukinumab at enrollment in the Corrona Psoriasis Registry and had a 6-month follow-up visit (window: 5-9 months) as of December 31 2017, were included in the analysis. Measures of disease severity and PROs were assessed in patients who maintained secukinumab treatment at the 6-month follow-up visit. Results: Of the 144 patients who initiated secukinumab at enrollment and had a 6-month follow-up visit, 118 (81.9%) maintained secukinumab treatment at 6 months and demonstrated significant improvements in affected body surface area (BSA) and 5-point Investigator's Global Assessment (IGA) score (all p < .01). The majority of patients were biologic experienced (89.8%). In addition, patients reported significant improvements in quality of life, as well as in pain, itch, fatigue, work productivity, and daily activities (all p < .01).Conclusions: Secukinumab significantly improved disease severity and PROs after 6 months of follow-up in this real-world study, which is consistent with other current real-world studies.
Objective: To examine the real-world effectiveness of secukinumab with regard to clinical and patient-reported outcomes (PROs) from enrollment to a 6-month follow-up visit in patients with psoriasis in the Corrona Psoriasis Registry. Methods: Eligible patients aged ≥ 18 years who initiated secukinumab at enrollment in the Corrona Psoriasis Registry and had a 6-month follow-up visit (window: 5-9 months) as of December 31 2017, were included in the analysis. Measures of disease severity and PROs were assessed in patients who maintained secukinumab treatment at the 6-month follow-up visit. Results: Of the 144 patients who initiated secukinumab at enrollment and had a 6-month follow-up visit, 118 (81.9%) maintained secukinumab treatment at 6 months and demonstrated significant improvements in affected body surface area (BSA) and 5-point Investigator's Global Assessment (IGA) score (all p < .01). The majority of patients were biologic experienced (89.8%). In addition, patients reported significant improvements in quality of life, as well as in pain, itch, fatigue, work productivity, and daily activities (all p < .01).Conclusions: Secukinumab significantly improved disease severity and PROs after 6 months of follow-up in this real-world study, which is consistent with other current real-world studies.
Authors: Jessica A Walsh; Kristina Callis Duffin; Abby S Van Voorhees; Soumya D Chakravarty; Timothy Fitzgerald; Amanda Teeple; Katelyn Rowland; Jonathan Uy; Robert R McLean; Wendi Malley; Angel Cronin; Joseph F Merola Journal: Dermatol Ther (Heidelb) Date: 2021-11-25
Authors: April W Armstrong; Dhaval Patil; Eugenia Levi; Catherine B McGuiness; Xin Wang; Yi Wang; Chi-Chang Chen; Elizabeth Nguyen; Paul S Yamauchi Journal: Dermatol Ther (Heidelb) Date: 2021-08-28
Authors: Bruce Strober; Dhaval Patil; Robert R McLean; Melissa Moore-Clingenpeel; Ning Guo; Eugenia Levi; Mark Lebwohl Journal: Dermatol Ther (Heidelb) Date: 2022-05-13